六基因白血病干细胞评分识别高危儿童急性髓系白血病
研究基于AML02试验中163例儿童AML患者,利用Cox-LASSO回归开发了六基因白血病干细胞评分(pLSC6),并在AML-TARGET项目205例患者中验证。低pLSC6组5年无事件生存率为78.3%,高危组为34.5%(P<0.00001),pLSC6在多因素模型中仍与EFS和OS显著相关,并可预测移植患者结局。
要点
- pLSC6评分可区分儿童AML高危与低危,低评分组5年EFS为78.3%,高评分组为34.5%。
- pLSC6在调整诱导后MRD、危险分组、FLT3状态、WBC和年龄后仍与EFS和OS显著相关。
- pLSC6在AML-TARGET队列中验证,并可能作为移植转诊的参考标准。
核心结论
- pLSC6评分有望重新定义儿童AML初始危险分层并识别高危患者。
研究设计与样本
- 基于AML02多中心临床试验(NCT00136084)中163例儿童AML患者,利用Cox-LASSO回归构建pLSC6评分。
- 在AML-TARGET项目205例儿童AML患者数据中验证pLSC6的预后价值。
主要发现
- AML02队列中低pLSC6组(n=97)5年EFS为78.3%(95%CI=70.5-86.9%),高pLSC6组(n=66)为34.5%(95%CI=24.7-48.2%),P<0.00001。
- 调整诱导1-MRD状态、危险分组、FLT3状态、诊断时WBC计数和年龄后,pLSC6仍与EFS和OS显著相关。
- 在AML-TARGET验证队列中,单预测和多预测Cox回归模型均证实pLSC6的预后价值。
- 两个队列中pLSC6均可预测移植患者结局。
临床怎么用
- pLSC6评分可用于儿童AML初始危险分层,识别高危患者。
- 高pLSC6评分可能作为移植转诊的参考标准。
- pLSC6评分有助于指导开发新的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, mRNA-expression signature enriched in LSCs was used to create a 17-gene leukemic stem cell (LSC17) score predictive of prognosis in adult AML. By fitting a Cox-LASSO regression model to the clinical outcome and gene-expression levels of LSC enriched genes in 163 pediatric participants of the AML02 multi-center clinical trial (NCT00136084), we developed a six-gene LSC score of prognostic value in pediatric AML (pLSC6). In the AML02 cohort, the 5-year event-free survival (EFS) of patients within low-pLSC6 group (n = 97) was 78.3 (95% CI = 70.5-86.9%) as compared with 34.5(95% CI = 24.7-48.2 %) in patients within high-pLSC6 group (n = 66 subjects), p < 0.00001. pLSC6 remained significantly associated with EFS and overall survival (OS) after adjusting for induction 1-MRD status, risk-group, FLT3-status, WBC-count at diagnosis and age. pLSC6 formula developed in the AML02 cohort was validated in the pediatric AML-TARGET project data (n = 205), confirming its prognostic value in both single-predictor and multiple-predictor Cox regression models. In both cohorts, pLSC6 predicted outcome of transplant patients, suggesting it as a useful criterion for transplant referrals. Our results suggest that pLSC6 score holds promise in redefining initial risk-stratification and identifying poor risk AML thereby providing guidance for developing novel treatment strategies.
引用
- Elsayed AH, Rafiee R, Cao X, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2019. PMID: 31645648. doi:10.1038/s41375-019-0604-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。